In a positive development for the problem-ridden company, on 11 July, Lundbeck received the much anticipated FDA approval for its second-generation atypical anti-psychotic drug Rexulti (Brexpiprazole) – co-developed with Otsuka Pharmaceuticals – for both schizophrenia as monotherapy and major depressive disorder (MDD) as adjunctive treatment. Brexpiprazole is the third atypical anti-psychotic to gain approval in the US market (after Otsuka’s Abilify and AstraZeneca’s S
16 Jul 2015
Brexpiprazole’s approval - the remedy to Lundbeck’s depression?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Brexpiprazole’s approval - the remedy to Lundbeck’s depression?
In a positive development for the problem-ridden company, on 11 July, Lundbeck received the much anticipated FDA approval for its second-generation atypical anti-psychotic drug Rexulti (Brexpiprazole) – co-developed with Otsuka Pharmaceuticals – for both schizophrenia as monotherapy and major depressive disorder (MDD) as adjunctive treatment. Brexpiprazole is the third atypical anti-psychotic to gain approval in the US market (after Otsuka’s Abilify and AstraZeneca’s S